Association of Hormonal Contraceptive Use with Headache and Temporomandibular Pain: The OPPERA Study

Aims: To determine the relationship between hormonal contraceptive (HC) use and painful symptoms, particularly those associated with headache and painful temporomandibular disorders (TMD). Methods: Data from the Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) prospective cohort study were used. During the 2.5-year median follow-up period, quarterly health update (QHU) questionnaires were completed by 1,475 women aged 18 to 44 years who did not have TMD, menopause, hysterectomy, or hormone replacement therapy use at baseline. QHU questionnaires evaluated HC use, symptoms of headache and TMD, and pain of ≥ 1 day duration in 12 body regions. Participants who developed TMD symptoms were examined to classify clinical TMD. Headache symptoms were classified based on the International Classification of Headache Disorders 3 (ICHD-3). Associations between HC use and pain symptoms were analyzed using generalized estimating equations and Cox models. Results: HC use, endorsed in 33.7% of QHU questionnaires, was significantly associated with concurrent symptoms of TMD (odds ratio [OR]: 1.20, 95% CI: 1.06 to 1.35) and headache (OR: 1.26, 95% CI: 1.11 to 1.43). HC use was also significantly associated with concurrent pain of ≥ 1 day duration in the head (OR: 1.38, 95% CI: 1.16 to 1.63), face (OR: 1.44, 95% CI: 1.13 to 1.83), and legs (OR: 1.22, 95% CI: 1.01 to 1.47), but not elsewhere. Initiation of HC use was associated with increased odds of subsequent TMD symptoms (OR: 1.37, 95% CI: 1.13 to 1.66) and pain of ≥ 1 day in the head (OR: 1.37, 95% CI: 1.01 to 1.85). Discontinuing HC use was associated with lower odds of subsequent headache (OR: 0.82, 95% CI: 0.67 to 0.99). HC use was not significantly associated with subsequent onset of examiner-classified TMD. Conclusion: These findings imply that HC influences craniofacial pain, and that this pain diminishes after cessation of HC use.

contraception; facial pain; headache; hormones; pain

1. Linn ES. Hormonal contraceptive methodology: An historical review. Int J Fertil Womens Med 2005;50:88–96.

2. Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. Am J Obstet Gynecol 2005;193:636–649.

3. MacGregor EA. Contraception and headache. Headache 2013;53:247–276.

4. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd. Sex, gender, and pain: A review of recent clinical and experimental findings. J Pain 2009;10:447–485.

5. LeResche L, Saunders K, Von Korff MR, Barlow W, Dworkin SF. Use of exogenous hormones and risk of temporomandibular disorder pain. Pain 1997;69:153–160.

6. Hatch JP, Rugh JD, Sakai S, Saunders MJ. Is use of exogenous estrogen associated with temporomandibular signs and symptoms? J Am Dent Assoc 2001;132:319–326.

7. Functional pain disorders: Time for a paradigm shift? In: Mayer EA, Bushnell MC (eds). Functional Pain Syndromes: Presentation and Pathophysiology. Seattle: IASP Press, 2009:531–566.

8. French L. Dysmenorrhea. Am Fam Physician 2005;15:285–291.

9. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009;CD002120.

10. Maixner W, Diatchenko L, Dubner R, et al. Orofacial pain prospective evaluation and risk assessment study–the OPPERA study. J Pain 2011;12(suppl):T4-11.e1-2.

11. Slade GD, Bair E, By K, et al. Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. J Pain 2011;12:T12–T26.

12. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301–355.

13. Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): Current status and future revisions. Cephalalgia 2006;26:1409–1420.

14. Tchivileva IE, Ohrbach R, Fillingim RB, Greenspan JD, Maixner W, Slade GD. Temporal change in headache and its contribution to risk of developing first-onset TMD in the OPPERA study. Pain 2017;158:120–129.

15. Arnold M. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia 2018;38: 1–211.

16. Bair E, Brownstein NC, Ohrbach R, et al. Study protocol, sample characteristics, and loss to follow-up: The OPPERA prospective cohort study. J Pain 2013;14(suppl):T2–T19.

17. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965;58:295–300.

18. Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol 2014;27:315–324.

19. Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: No adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010;63:64–74.

20. Mannix LK. Menstrual-related pain conditions: Dysmenorrhea and migraine. J Womens Health (Larchmt) 2008;17:879–891.

21. Berkson J. Limitations of the application of fourfold table analy-sis to hospital data. Biometrics 1946;2:47–53.

22. Craft RM. Modulation of pain by estrogens. Pain 2007; 132(suppl):s3–s12.

23. Cairns BE. The influence of gender and sex steroids on cranio-facial nociception. Headache 2007;47:319–324.

24. Yamagata K, Sugimura M, Yoshida M, et al. Estrogens exacerbate nociceptive pain via up-regulation of TRPV1 and ANO1 in trigeminal primary neurons of female rats. Endocrinology 2016;157:4309–4317.

25. Bi RY, Meng Z, Zhang P, Wang XD, Ding Y, Gan YH. Estradiol upregulates voltage-gated sodium channel 1.7 in trigeminal ganglion contributing to hyperalgesia of inflamed TMJ. PloS One 2017;12:e0178589.

26. Tashiro A, Okamoto K, Bereiter DA. Rapid estrogenic effects on TMJ-responsive brainstem neurons. J Dent Res 2012;91: 210–214.

27. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006;26:5777–5785.

28. Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ. Oral contraceptives and increased headache prevalence: The Head-HUNT Study. Neurology 2006;66:349–353.

29. Ahrendt HJ, Karck U, Pichl T, Mueller T, Ernst U. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: Results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007;12:354–361.